The impact of the COVID-19 infection epidemic on the provision of health care for people living with HIV


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate the impact of the novel coronavirus infection (COVID-19) epidemic on the provision of health care for HIV infection and the prevalence of COVID-19 among people living with HIV (PLHIV). Materials and methods. The investigation was conducted using an anonymous survey on the Internet from July 08 to 31, 2020. The responses of590 HIV-positive respondents and 262 HIV-negative ones were an investigation object. Results. The COVID-19 pandemic demonstrated a negative impact on the provision of health care for HIV infection in the Russian Federation; however, the size of this problem was not as large as expected. Among PLHIV on antiretroviral therapy (ART), 70.5% reported that they had no problems in receiving antiretroviral drugs (ARVDs). 4.1% missed ARVDs due to the inability to get them at the AIDS center. Symptoms characteristic of COVID-19 were present in the majority of PLHIV (55.3%); while 52.7% of the HIV-negative respondents were examined for COVID-19, as were only 28.1% among PLHIV. Among PLHIV, 23.5% were found to have markers for COVID-19 (95% CI, 17.5-30.7). Among the HIV-negative respondents, 6.5% were positive for COVID-19(95% CI, 2.9-10.9). 41.4% of PLHIV reported COVID-19 to the AIDS center. The majority of PLHIV respondents who had experienced coronavirus infection were men (51.3%), those who were aged 35-44years (71.8%), and had a long life experience with HIV. The respondents predominantly reported that their condition was moderate during COVID-19. Conclusion. The investigation showed the negative impact of the COVID-19 pandemic on the provision of health care for HIV infection in the Russian Federation, but the majority of respondents who identified themselves as PLHIV reported that they had no problems in receiving ARVDs. Among the study participants, those who identified themselves as HIV-infected were probably more susceptible to COVID-19 than respondents who identified themselves as HIV-negative. In the presence of symptoms characteristic of COVID-19, PLHIV were 2 times less likely than HIV-negative respondents to be examined for coronavirus infection and less likely to seek medical advice.

Full Text

Restricted Access

About the authors

Natalia N. Ladnaia

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: nladnaia@hotmail.com
Cand. Biol. Sci., Senior Researcher

Nadezhda V. Kozyrina

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: nad-kozyrina@yandex.ru
Cand. Med. Sci., Researcher

Ksenia A. Babikhina

Treatment Preparedness Coalition

Email: kbabikhina@itpcru.org
Monitoring Expert

Alexey V. Mikhailov

Treatment Preparedness Coalition

Email: aleksey.mikhailov@itpcru.org
Head of Monitoring Section

Natalia V. Egorova

Treatment Preparedness Coalition

Email: egorova@itpcru.org
Monitoring Expert

M. V Godlevskaya

«E.B.A.» Association

Email: m.godlevskaya@gmail.com

Marina V. Semenchenko

UNAIDS Regional Office for Eastern Europe and Central Asia

Email: semenchenkom@unaids.org
Cand. Med. Sci., Regional Adviser

Lev S. Zograbyan

UNAIDS Regional Office for Eastern Europe and Central Asia

Email: zohrabyanl@unaids.org
Cand. Med. Sci., Strategic Information Adviser

Vadim V. Pokrovsky

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: pokrovsky.vad@yandex.ru
Academician of the Russian Academy of Sciences, MD, Head, HIV Department

References

  1. Coronavirus disease ( COVID-19) Situation Report - 163. Data as received by WHO from national authorities by 10:00 CEST, 1 July 2020. WHO, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200701- COVID-19-sitrep-163.pdf?sfvrsn=c202f05b_2
  2. COVID-19 Weekly Epidemiological Update. Edition 46, published 29 June 2021. WHO, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-oncovid-19-29-june-2021
  3. Информационный бюллетень 2021 г. Предварительные эпидемиологические оценочные данные. ЮНЭЙДС, 2021. https://www.unaids.org/ru/resources/fact-sheet [Global HIV & AIDS statistics. Fact sheet, 2021. HIV ESTIMATES]. UNAIDS, 2021. https://www.unaids.org/ru/resources/fact-sheet
  4. Blanco J.L., Ambrosioni J., Garcia F., Martinez E., Soriano A., Mallolas J. et al. COVID-19 in HIV Investigators. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020; Apr 15. pii: S2352-3018(20)30111-9
  5. Harter G., Spinner C.D., Roider J., Bickel M., Krznaric I., Grunwald S. et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection 2020, May 11. doi: 10.1007/s15010-020-01438-z
  6. Gervasoni C., Meraviglia P., Riva A., Giacomelli A., Oreni L., Minisci D. et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin. Infect. Dis. 2020, May 14. pii: ciaa579. doi: 10.1093/cid/ciaa579
  7. Guo W., Ming F., Dong Y. et al. A Survey for COVID-19 among HIV/AIDS Patients in Two Districts of Wuhan, China. Preprint research paper, The Lancet, 2020.
  8. Wu Q., Chen T., Zhang H. Recovery from COVID-19 in two patients with coexisted HIV infection. J. Med. Virol. 2020, May 13. doi: 10.1002/jmv.26006
  9. Karmen-Tuohy S., Carlucci P.M., Zacharioudakis I.M., Zervou F.N., Rebick G. et al. Outcomes among HIV-positive patients hospitalized with COVID-19. medRxiv. https://www.medrxiv.org/content/10.1101/2020.05.07.20094797v1
  10. Docherty A.B., Harrison E.M., Green C.A. et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterization protocol. medRxiv preprint. DOI: https://doi.org/10.1101/2020.04.23.20076042
  11. Inciartea A., Gonzalez-Cordona A., Rojasa J. et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS 2020; 34(12): 1775-1780. doi: 10.1097/QAD. 0000000000002643
  12. Gao Z., Xu Y., Sun C., Wang X., Guo Y., Qiu S. et al. A systematic review of asymptomatic infections with COVID-19. J. Microbiol. Immunol. Infect. 202010.1016/j. jmii.2020.05.001. doi: 10.1016/j.jmii.2020.05.001
  13. Wang Q.Q., Kaelber D.C. Xu, R. et al. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol. Psychiatry (2020). https://doi.org/10.1038/s41380-020-00880-7
  14. Ssentongo P., Heilbrunn E.S., Ssentongo A.E. et al. Prevalence of HIV in patients hospitalized for COVID-19 and associated mortality outcomes: a systematic review and meta-analysis. Presented at: IDWeek 2020; October 21-25, 2020. Poster 393. https://www.infectiousdiseaseadvisor.com/home/meetings/idweek-2020-hiv-in-depth/people-with-hiv-higher-susceptibility-and-mortality-to-coronavirus-in-us/
  15. Дробышевская Е.В., Жукова Е.В., Ватулян А.К. Клинико-эпидемиологическая характеристика пациентов с сочетанной патологией ВИЧ + COVID-19 в Московской области. Сборник тезисов VIII Конгресса с международным участием «Контроль и профилактика инфекций, связанных с оказанием медицинской помощи (ИСМП-2020)». М.: ЦНИИ эпидемиологии Роспотребнадзора, 2020
  16. Cao B., Wang Y., Wen D. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19. N. Engl. J. Med. 2020. doi: 10.1056/NEJMoa2001282
  17. Q&A: HIV, antiretrovirals and COVID-19? WHO, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-on-COVID-19-hiv-and-antiretrovirals

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies